Hypertension in blacks;Hypertension artérielle du sujet noir

Presse Medicale

Volumn 35, Issue 6 II, 2006, Pages 1067-1071

  Fauvel, Jean Pierre ^a   Laville, Maurice ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

CARDIOVASCULAR RISK; DRUG EFFICACY; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY INJURY; MORBIDITY; REVIEW; RISK FACTOR; SALT INTAKE;

EID: 33745271037     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(06)74749-2     Document Type: Article

References (42)

1. Barr DA. The practitioner's dilemma: Can we use a patient's race to predict genetics, ancestry, and the expected outcomes of treatment? Ann Intern Med. 2005;143: 809-15.
2. Hertz RP, Unger AN, Cornell JA, Saunders E. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med. 2005; 165: 2098-104.
3. Inamo J, Lang T, Atallah A, Inamo A, Larabi L, Chatellier G et al. INHAPAG Study Group. Prevalence and therapeutic control of hypertension in French Caribbean regions. J Hypertens. 2005; 23: 1341-6.
4. Hinderliter AL, Sager AR, Sherwood A, Light KC, Girdler SS, Willis PW. Ethnic differences in forearm vasodilator capacity. Am J Cardiol. 1996; 78: 208-11.
5. Cardillo C, Kilcoyne CM, Cannon RO Panza JA. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension. 1998; 31: 1235-9.
6. Campia U, Choucair WK, Bryant MB, Waclawiw MA, Cardillo C, Panza JA. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol. 2002; 40: 754-60.
7. Aviv A, Hollenberg NK, Weder A. Urinary potassium excretion and sodium sensitivity in blacks. Hypertension. 2004; 43: 707-13.
8. Aviv A, Hollenberg NK, Weder AB. Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans. Kidney Int. 2004; 65: 361-8.
9. Dekkers C, Treiber FA, Kapuku G, Van Den Oord EJ, Snieder H. Growth of left ventricular mass in African American and European American youth. Hypertension. 2002; 39: 943-51.
10. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989; 13: 180-93.
11. Jones DW, Chambless LE, Folsom AR, Heiss G, Hutchinson RG, Sharrett AR et al. Risk factors for coronary heart disease in African Americans: the atherosclerosis risk in communities study, 1987-1997. Arch Intern Med. 2002; 162: 2565-71.
12. Alderman MH, Cohen HW, Madhavan S. Myocardial infarction in treated hypertensive patients: the paradox of lower incidence but higher mortality in young blacks compared with whites. Circulation. 2000; 101: 1109-14.
13. Burchfiel CM, Skelton TN, Andrew ME, Garrison RJ, Arnett DK, Jones DW et al. Metabolic Syndrome and Echocardiographic Left Ventricular Mass in Blacks: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2005; 112: 819-27.
14. Cooper RS, Psaty BM. Should ethnicity serve as the basis for clinical trial design? Diversity and inclusiveness should remain the guiding principles for clinical trials. Circulation. 2005; 112: 3660-5.
15. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE et al. for the ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293: 1595-608.
16. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995; 25: 587-94.
17. Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002; 13: 2363-70.
18. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997; 277: 1293-8.
19. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004; 15: 1307-15.
20. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997; 336: 1117-24.
21. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001; 344: 3-10.
22. Moser M, Lunn J. Responses to captopril and hydrochlorothiazide in black patients with hypertension. Clin Pharmacol Ther. 1982; 32: 307-12.
23. Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den Hond E et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Intern Med. 2001; 161: 965-71.
24. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003; 41: 1148-55.
25. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med. 2000; 160: 825-31.
26. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al. African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-31.
27. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K et al. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004; 351: 2049-57.
28. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM et al. The Hypertension in African Americans Working Group. Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163: 525-41.
29. Julius S, Alderman MH, Beevers G, Dahlof B, Devereux RB, Douglas JG et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The life study. JACC. 2004; 43: 1047-55.
30. Albert MA, Torres J, Glynn RJ, Ridker PM. Perspective on selected issues in cardiovascular disease research with a focus on black Americans. Circulation. 2004;110: e7-12.
31. Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979; 242: 2572-7.
32. Connett JE, Stamler J. Responses of black and white males to the special intervention program of the Multiple Risk Factor Intervention Trial. Am Heart J. 1984; 108: 839-48.
33. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265: 3255-64.
34. Wong M, Johnson G, Shabetai R, Hughes V, Bhat G, Lopez B, Cohn JN. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87(6 Suppl): 65-70.
35. Zanchetti A, Hansson L, Dahlof B, Elmfeldt D, Kjeldsen S, Kolloch R et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens. 2001; 19: 1149-59.
36. Liebson PR, Grandits G, Prineas R, Dianzumba S, Flack JM, Cutler JA et al. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1993; 87: 476-86.
37. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338: 645-52.
38. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, Neaton JD et al. CONVINCE Research Group. Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. J Hypertens. 2005; 23: 1099-106.
39. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317: 703-13.
40. Hebert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension. 1997; 30: 428-35.
41. de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney Int. 2006; 69: 1675-82.
42. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851-60.